share_log

BioVie | 424B5: Prospectus

SEC ·  Mar 4 17:35

Summary by Moomoo AI

BioVie Inc., a clinical-stage company focusing on the development of innovative drug therapies, has announced the offering of 15,000,000 shares of its Class A common stock at $1.00 per share, alongside pre-funded warrants to purchase up to 6,000,000 shares of common stock and warrants to purchase up to 10,500,000 shares of common stock. The pre-funded warrants are exercisable at $0.0001 per share, with a purchase price of $0.9999 each, and are immediately exercisable. The common warrants have an exercise price of $1.50 per share, are also immediately exercisable, and will expire five years from the issuance date. The shares and warrants are being sold together but will be issued separately and are immediately separable upon issuance. ThinkEquity LLC has been engaged as the exclusive...Show More
BioVie Inc., a clinical-stage company focusing on the development of innovative drug therapies, has announced the offering of 15,000,000 shares of its Class A common stock at $1.00 per share, alongside pre-funded warrants to purchase up to 6,000,000 shares of common stock and warrants to purchase up to 10,500,000 shares of common stock. The pre-funded warrants are exercisable at $0.0001 per share, with a purchase price of $0.9999 each, and are immediately exercisable. The common warrants have an exercise price of $1.50 per share, are also immediately exercisable, and will expire five years from the issuance date. The shares and warrants are being sold together but will be issued separately and are immediately separable upon issuance. ThinkEquity LLC has been engaged as the exclusive placement agent for the offering. The placement agent will use reasonable best efforts to arrange for the sale of the securities, but is not required to sell any specific number or dollar amount. The offering is expected to close on or about March 6, 2024, subject to customary closing conditions. The date of the prospectus supplement is March 4, 2024.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more